Literature DB >> 6594505

Dose-dependent pharmacokinetic study of pefloxacin, a new antibacterial agent, in humans.

J Barre, G Houin, J P Tillement.   

Abstract

A dose-dependent pharmacokinetic study of pefloxacin was performed after four intravenous infusions and four orally administered doses. After intravenous infusion, the pharmacokinetic profiles of the plasma concentrations showed a biphasic decline, with half-lives (mean +/- SD) of 8.55 +/- 4.20 min and 11.50 +/- 1.75 h, respectively. Intravenous infusion and oral administration yielded similar results. The pharmacokinetic parameters remained constant in the dose range of 200-800 mg from the plasma and urine data.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6594505     DOI: 10.1002/jps.2600731014

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  32 in total

1.  Penetration of pefloxacin into maxillary sinus cavity and nasal secretions.

Authors:  G Petrikkos; P Goumas; E Moschovakis; H Giamarellou
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-09       Impact factor: 3.267

Review 2.  Treatment of genitourinary tract infections with fluoroquinolones: activity in vitro, pharmacokinetics, and clinical efficacy in urinary tract infections and prostatitis.

Authors:  J S Wolfson; D C Hooper
Journal:  Antimicrob Agents Chemother       Date:  1989-10       Impact factor: 5.191

3.  Concentrations of pefloxacin in plasma and tissue after administration as surgical prophylaxis.

Authors:  B Jacoberger; G Ubeaud; G Freys; T Pottecher; L Jung; J C Koffel
Journal:  Antimicrob Agents Chemother       Date:  1998-02       Impact factor: 5.191

4.  Pharmacokinetics of a novel quinolone, AT-4140, in animals.

Authors:  S Nakamura; N Kurobe; T Ohue; M Hashimoto; M Shimizu
Journal:  Antimicrob Agents Chemother       Date:  1990-01       Impact factor: 5.191

5.  Structure-absorption relationships of a series of 6-fluoroquinolones.

Authors:  E Escribano; A C Calpena; T M Garrigues; J Freixas; J Domenech; J Moreno
Journal:  Antimicrob Agents Chemother       Date:  1997-09       Impact factor: 5.191

6.  Pharmacokinetics and bactericidal activities of one 800-milligram dose versus two 400-milligram doses of intravenously administered pefloxacin in healthy volunteers.

Authors:  O Petitjean; B Pangon; N Brion; M Tod; C Chaplain; V Le Gros; K Louchahi; P Allouch
Journal:  Antimicrob Agents Chemother       Date:  1993-04       Impact factor: 5.191

Review 7.  Pefloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  J P Gonzalez; J M Henwood
Journal:  Drugs       Date:  1989-05       Impact factor: 9.546

8.  Activities of various quinolone antibiotics against Mycobacterium leprae in infected mice.

Authors:  R H Gelber; A Iranmanesh; L Murray; P Siu; M Tsang
Journal:  Antimicrob Agents Chemother       Date:  1992-11       Impact factor: 5.191

9.  Penetration of ciprofloxacin and fleroxacin into biliary tract.

Authors:  C E Edmiston; E C Suarez; A P Walker; M P Demeure; C T Frantzides; W J Schulte; S D Wilson
Journal:  Antimicrob Agents Chemother       Date:  1996-03       Impact factor: 5.191

10.  Randomized, double-blind comparison of single-dose regimens of rufloxacin and pefloxacin for acute uncomplicated cystitis in women. French Multicenter Urinary Tract Infection-Rufloxacin Group.

Authors:  A Jardin; M Cesana
Journal:  Antimicrob Agents Chemother       Date:  1995-01       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.